Revive Therapeutics Explores the Use of Bucillamine for Long COVID

by rvvadmin | Feb 1, 2024 | 2024

TORONTO, Aug. 22, 2023 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today...

Revive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500

by rvvadmin | Jan 31, 2024 | 2024

TORONTO, Aug. 22, 2023 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today...

Revive Therapeutics Ltd. Announces Offering of Up to $3 Million

by rvvadmin | Jan 24, 2024 | 2024

TORONTO, Aug. 22, 2023 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today...

Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada

by rvvadmin | Jan 16, 2024 | 2024

TORONTO, Aug. 22, 2023 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today...

Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine

by rvvadmin | Jan 10, 2024 | 2024

TORONTO, Aug. 22, 2023 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today...